Among the most-read stories in hematology and oncology this week were the FDA’s approval of Keytruda, in combination with chemotherapy, for treating first-line metastatic squamous non-small cell lung cancer and a report that showed combining Hu5F9-G4 and rituximab led to promising results in patients with relapsed or refractory non-Hodgkin lymphoma.
Readers were also interested in learning more about the benefit of nivolumab plus low-dose ipilimumab in certain patients with metastatic colorectal cancer, a poll that showed how many Americans believe cancer is exclusively cured by treatments such as diet and results of a phase 3 trial that assessed the addition of daratumumab to lenalidomide and dexamethasone for some patients with multiple myeloma. – by Janel Miller
FDA approves Keytruda plus chemotherapy for first-line metastatic squamous non-small cell lung cancer
The FDA approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of metastatic squamous non-small cell lung cancer. Read more.
Combination shows promise in relapsed, refractory non-Hodgkin lymphoma
The combination of Hu5F9-G4 and rituximab demonstrated promising activity among patients with relapsed or refractory non-Hodgkin lymphoma, according to results of a phase 1b study published in The New England Journal of Medicine. Read more.
Nivolumab plus low-dose ipilimumab demonstrates ‘robust’ benefit for certain patients with metastatic colorectal cancer
MUNICH — The combination of nivolumab and low-dose ipilimumab may become a new first-line treatment option for patients with microsatellite instability-high metastatic colorectal cancer, according to results from the phase 2 CheckMate-142 trial presented at European Society for Medical Oncology Congress. Read more.
Survey: 4 in 10 Americans believe alternative treatments can cure cancer
About four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology’s second annual National Cancer Opinion Survey. Read more.
Frontline daratumumab regimen extends progression-free survival in multiple myeloma
A randomized phase 3 trial to evaluate the addition of daratumumab to lenalidomide and dexamethasone for the frontline treatment of patients with multiple myeloma met its primary endpoint of progression-free survival, according to the agent’s manufacturer.